This significant milestone makes Tremfya the latest addition to the IL-23 class in Crohn’s, joining AbbVie’s Skyrizi (risankizumab) and Eli Lilly’s Omvoh (mirikizumab), all now available for ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

For some people with ulcerative colitis (UC), consuming gluten can trigger or worsen symptoms like abdominal pain, bloating, and diarrhea, potentially leading to more frequent or severe flare-ups ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...

Crohn’s disease and ulcerative colitis are both inflammatory bowel diseases with similar symptoms. However, some key differences include the areas they affect, diagnostic tools, and treatment ...

The American Gastroenterological Association recently revised its guidelines for treating ulcerative colitis, recommending other options like Remicade, J&J’s Simponi, Takeda’s Entyvio, Gilead and ...

In addition to both tirzepatide brands, Lilly expects increasing contributions from four recently launched therapies: Jaypirca, Ebglyss, Omvoh, and Kisunla. It also looks like this big pharma ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study ...

Other IL-23 inhibitors approved for Crohn's disease include risankizumab (Skyrizi) and mirikizumab (Omvoh). Common adverse events (≥3%) with guselkumab in the Crohn's disease trials included ...